Orphan Drugs- development trends and strategies

The growth of pharma industries has slowed in recent years because of various reasons such as patent expiries, generic competition, drying pipelines, and increasingly stringent regulatory guidelines. Many blockbuster drugs will lose their exclusivity in next 5 years. Therefore, the current economic situation plus the huge generic competition shifted the focus of pharmaceutical companies from the essential medicines to the new business model — niche busters, also called orphan drugs.

  • Cost of drug development
  • Evidence-based policy making & commissioning
  • Orphan drug status- Various Probabilities
  • Challenges in assessing clinical relevance and cost effectiveness
  • Developments in Regulating Orphan Drug Approval

Related Conference of Orphan Drugs- development trends and strategies

October 30-November 1, 2017

3rd Annual Congress on Rare Diseases and Orphan Drugs


(10 Plenary Forums - 1 Event)
San Antonio, Texas, USA
March 1-2, 2018

5th International congress on Infectious Diseases

Berlin, Germany
June 11-12, 2018

4th World Congress on Rare Diseases and Orphan Drugs

Dublin, Ireland
July 23-25, 2018

11th World Congress on Infectious Diseases and Therapy

Melbourne, Australia
August 27-28, 2018

9th International Conference on Emerging Infectious Diseases

Zurich, Switzerland
September 17-18, 2018

4th Annual Congress on Infectious Diseases

San Diego, USA
September 27-29, 2018

10thEuro-Global Conference on Infectious Diseases

Rome, Italy
Sep 17-18, 2018

3rd International Conference on Infection Control

San Diego, California, USA

Orphan Drugs- development trends and strategies Conference Speakers

Recommended Sessions

Related Journals

Are you interested in